Abigail Brooks is an assistant editor for HCPLive. She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books.
Achieving SVR Reduces Risk of Cardiovascular Events in Patients with HCV
February 17th 2024Results highlight the benefit of achieving sustained virological response with DAAs for decreasing patients’ risk of carotid atherosclerosis and peripheral artery disease, especially among those with severe fibrosis.
Read More
Sustained Virologic Response Shown to Improve Quality of Life in Patients with Chronic HCV
February 4th 2024Sustained virologic response (SVR) and sociodemographic factors were found to be associated with long-term improvements in health-related quality of life in patients with hepatitis C (HCV).
Read More
HBV Markers, Reactivation Do Not Impact Effectiveness of Direct-Acting Antivirals for HCV
January 16th 2024Response to direct-acting antiviral therapy was similar between patients with and without HBV coinfection, with most patients completing the planned course of treatment and achieving SVR, even in the case of HBV reactivation.
Read More
Black Patients Receive Less HAI Testing Despite Similar Positivity Rates to White Patients
January 15th 2024A retrospective cohort study of inpatient encounters from 3 hospitals in the Duke University Health System showed greater rates of testing among White patients compared to Black and NWNB patients.
Read More
DAAs Reduce Iron Parameters in Patients with Hepatitis C, Hyperferritinemia
January 8th 2024Statistically significant reductions in serum ferritin, transferrin saturation index, and iron levels were observed after treatment, with hyperferritinemia eradicated in nearly all patients treated with DAAs achieving SVR.
Read More
2 Antibiotics Show Similar Efficacy for Healthcare-Associated Infection
September 27th 2023Patients treated with oral metronidazole experienced significantly more first-line drug changes compared to those on fidaxomicin; although there were no significant differences observed in the global or clinical cure rate between the 2 treatments.
Read More